<DOC>
	<DOCNO>NCT02276872</DOCNO>
	<brief_summary>This multi-center , open-label , safety , tolerability pharmacokinetic study oral treprostinil pediatric subject stable PAH age 7 17 year , ( 1 ) transition parenteral Remodulin therapy ; ( 2 ) transitioning inhaled prostacyclin therapy ; ( 3 ) currently receive prostacyclin therapy .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Oral Treprostinil Pediatric PAH Patients Aged 7 17 Years</brief_title>
	<detailed_description />
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>Between 7 17 year age , inclusive , date inform consent sign Cohort 3 : The subject must weigh minimum 22 kg Screening Current diagnosis PAH ( WHO Group I ) associate : 1 . Idiopathic heritable PAH 2 . Persistent PAH least one year follow surgical repair congenital systemictopulmonary cardiac shunt , congenital heart disease , congenital heart lesion clinically significant residual defect condition stabilize hemodynamically 3 . PAH subject unrepaired restrict atrial septal defect , ventricular septal defect , patent ductus arteriosus ; subject must rest post ductal oxygen saturation ( oxygen ) great 88 % Cohort 1 : The subject must receive parenteral Remodulin least 90 day without dose change least 30 day prior Baseline Cohort 2 : The subject must receive inhaled prostacyclin least 90 day current stable dose without change least 30 day prior Baseline All Cohorts : The subject must receive approved oral endothelin receptor antagonist , phosphodiesterase 5 inhibitor , and/or soluble guanylate cyclase stimulator least 90 day current stable dose , weightbased adjustment least 30 day prior first dose study drug Willing able swallow intact tablet whole without chewing , break , split Willing able comply dietary requirement associate oral treprostinil dose regimen On stable dos medical therapy 14 day prior Baseline visit dose adjustment , addition , discontinuation ( exception diuretic anticoagulant ) Diagnosis large unrestrictive ventricular septal defect patent ductus arteriosus , Eisenmenger syndrome , congenital diaphragmatic hernia , chronic lung disease , bronchopulmonary dysplasia , interstitial lung disease Current disease severity Panama functional class IIIb IV Previous exposure oral treprostinil Current diagnosis uncontrolled sleep apnea define physician Severe renal insufficiency define estimate creatinine clearance ( CrCl ) &lt; 30 mL/min ( Schwartz Formula ) requirement dialysis Screening Moderate severe hepatic dysfunction ; define elevate liver function test ( AST ALT ) great equal three time upper limit normal Screening , Child Pugh class B C hepatic disease Clinically significant anemia define hemoglobin and/or hematocrit level &lt; 75 % low limit normal range accord age gender Down syndrome Uncontrolled systemic hypertension evidence systolic diastolic blood pressure great 95th percentile age , height , gender Screening Baseline Subject and/or legal guardian has/have unstable psychiatric condition is/are mentally incapable understand objective , nature , consequence trial , condition Investigator 's opinion would constitute unacceptable risk subject 's safety Active infection , cardiovascular , liver , renal , hematologic , gastrointestinal , immunologic , endocrine , metabolic , central nervous system disease condition , opinion Investigator , may adversely affect safety subject interfere interpretation study assessment Actively list transplantation Receiving investigational drug , investigational device place participate investigational drug device study within 30 day prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pediatric</keyword>
	<keyword>treprostinil</keyword>
	<keyword>transition</keyword>
	<keyword>Remodulin</keyword>
</DOC>